A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:First line of the email MUST contain NCT # and Site #.
研究联系人备份
- 姓名:BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- 电话号码:855-907-3286
- 邮箱:Clinical.Trials@bms.com
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100142
- 尚未招聘
- Local Institution - 0038
-
接触:
- Site 0038
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 尚未招聘
- Local Institution - 0138
-
接触:
- Site 0138
-
-
Hubei
-
Wuhan、Hubei、中国、430030
- 尚未招聘
- Local Institution - 0050
-
接触:
- Site 0050
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- 尚未招聘
- Local Institution - 0147
-
接触:
- Site 0147
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200030
- 尚未招聘
- Local Institution - 0140
-
接触:
- Site 0140
-
Shanghai、Shanghai Municipality、中国、200032
- 尚未招聘
- Local Institution - 0169
-
接触:
- Site 0169
-
-
Sichuan
-
Chengdu、Sichuan、中国、610213
- 尚未招聘
- Local Institution - 0144
-
接触:
- Site 0144
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310016
- 尚未招聘
- Local Institution - 0137
-
接触:
- Site 0137
-
-
-
-
-
São Paulo、巴西、01246-000
- 尚未招聘
- Local Institution - 0001
-
接触:
- Site 0001
-
-
Rio Grande do Norte
-
Natal/RN、Rio Grande do Norte、巴西、59062-000
- 尚未招聘
- Local Institution - 0003
-
接触:
- Site 0003
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、91610-000
- 尚未招聘
- Local Institution - 0006
-
接触:
- Site 0006
-
-
São Paulo
-
Barretos、São Paulo、巴西、14784
- 尚未招聘
- Local Institution - 0005
-
接触:
- Site 0005
-
-
-
-
-
Cologne、德国、51109
- 招聘中
- Klinikum Köln-Merheim
-
接触:
- Eva-Lotte Buchmeier, Site 0065
- 电话号码:+49221890713962
-
Halle、德国、06120
- 招聘中
- Christliches Klinikum Halle (Saale) GmbH
-
接触:
- Miriam Moeller, Site 0042
- 电话号码:00493455591440
-
Hessen、德国、60590
- 招聘中
- Universitatsklinikum Frankfurt
-
接触:
- Friederike Althoff, Site 0125
-
-
Baden-Wurttemberg
-
Stuttgart、Baden-Wurttemberg、德国、70376
- 招聘中
- Robert Bosch Krankenhaus
-
接触:
- Martin Kimmich, Site 0126
- 电话号码:4971181017719
-
-
Hesse
-
Marburg、Hesse、德国、35043
- 尚未招聘
- Local Institution - 0156
-
接触:
- Site 0156
-
-
Saarland
-
Homburg、Saarland、德国、66424
- 尚未招聘
- Local Institution - 0152
-
接触:
- Site 0152
-
-
-
-
-
Bari、意大利、70124
- 尚未招聘
- Local Institution - 0043
-
接触:
- Site 0043
-
Milan、意大利、20142
- 尚未招聘
- Local Institution - 0159
-
接触:
- Site 0159
-
Ravenna、意大利、48121
- 尚未招聘
- Local Institution - 0014
-
接触:
- Site 0014
-
Rozzano (MI)、意大利、20089
- 尚未招聘
- Local Institution - 0011
-
接触:
- Site 0011
-
-
BG
-
Bergamo、BG、意大利、24127
- 尚未招聘
- Local Institution - 0148
-
接触:
- Site 0148
-
-
Catania
-
Misterbianco、Catania、意大利、95045
- 招聘中
- Humanitas Istituto Clinico Catanese
-
接触:
- Alessandro Russo, Site 0128
- 电话号码:393280569761
-
-
-
-
Santiago Metropolitan
-
Santiago、Santiago Metropolitan、智利、8420383
- 招聘中
- Bradfordhill
-
接触:
- Carlos Rojas, Site 0149
- 电话号码:+56998744662
-
Santiago、Santiago Metropolitan、智利、7500713
- 招聘中
- Orlandi Oncologia
-
接触:
- Francisco Orlandi, Site 0081
- 电话号码:56992214787
-
-
Valparaiso
-
Viña del Mar、Valparaiso、智利、2520598
- 招聘中
- Oncocentro Apys
-
接触:
- Alejandro Acevedo Gaete, Site 0084
- 电话号码:+56992369820
-
-
-
-
-
Grenoble、法国、38043 Cedex 09
- 尚未招聘
- Local Institution - 0047
-
接触:
- Site 0047
-
Marseille、法国、13915
- 招聘中
- Assistance Publique Hôpitaux de Marseille - Hôpital Nord
-
接触:
- Laurent Greillier, Site 0110
- 电话号码:33491324400
-
Paris、法国、75014
- 招聘中
- Hopitaux Universitaires Paris Centre-Hopital Cochin
-
接触:
- Marie Wislez, Site 0109
- 电话号码:33158413091
-
Saint-Herblain、法国、44800
- 尚未招聘
- Local Institution - 0085
-
接触:
- Site 0085
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、法国、6100
- 尚未招聘
- Local Institution - 0131
-
接触:
- Site 0131
-
-
Hérault
-
Montpellier、Hérault、法国、34090
- 招聘中
- Hôpital Arnaud de Villeneuve - CHU Montpellier
-
接触:
- Benoit Roch, Site 0117
- 电话号码:+33467330759
-
-
Languedoc-Roussillon
-
Montpellier、Languedoc-Roussillon、法国、34070
- 尚未招聘
- Local Institution - 0087
-
接触:
- Site 0087
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、法国、94800
- 尚未招聘
- Local Institution - 0119
-
接触:
- Site 0119
-
-
Île-de-France Region
-
Paris、Île-de-France Region、法国、75005
- 尚未招聘
- Local Institution - 0019
-
接触:
- Site 0019
-
-
-
-
New South Wales
-
Gosford、New South Wales、澳大利亚、2250
- 招聘中
- Gosford Hospital
-
接触:
- Matthew Chan, Site 0074
-
Westmead、New South Wales、澳大利亚、2145
- 尚未招聘
- Local Institution - 0134
-
接触:
- Site 0134
-
-
Queensland
-
Greenslopes、Queensland、澳大利亚、4120
- 尚未招聘
- Local Institution - 0167
-
接触:
- Site 0167
-
-
Victoria
-
Heidelberg、Victoria、澳大利亚、3084
- 尚未招聘
- Local Institution - 0100
-
接触:
- Site 0100
-
-
Western Australia
-
Perth、Western Australia、澳大利亚、6150
- 招聘中
- St. John of God Murdoch Hospital
-
接触:
- Kynan Feeney, Site 0048
- 电话号码:+61894389599
-
-
-
-
-
Bucharest、罗马尼亚、022328
- 招聘中
- Institutul Oncologic "Prof. Dr. Alexandru Trestioreanu" Bucuresti (IOB)
-
接触:
- Aurelia Alexandru, Site 0076
- 电话号码:40723289606
-
Cluj-Napoca、罗马尼亚、400015
- 招聘中
- Institutul Oncologic Cluj
-
接触:
- Tudor Ciuleanu, Site 0008
- 电话号码:40745646368
-
Craiova、罗马尼亚、200347
- 招聘中
- Centrul de Oncologie Sf. Nectarie SRL
-
接触:
- Michael Schenker, Site 0075
- 电话号码:40727774974
-
Iași、罗马尼亚、700483
- 招聘中
- Institutul Regional de Oncologie Iasi
-
接触:
- Dana Clement, Site 0116
- 电话号码:40744692062
-
Iași、罗马尼亚、700106
- 招聘中
- Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center)
-
接触:
- Constantin Volovat, Site 0115
- 电话号码:40746110096
-
Timisoara, Timis、罗马尼亚、300239
- 招聘中
- Oncohelp
-
接触:
- Daniela Sirbu, Site 0113
- 电话号码:40744571617
-
-
Cluj
-
Florești、Cluj、罗马尼亚、407280
- 招聘中
- Amethyst Radiotherapy Center-Oncologie Medicala
-
接触:
- Andrei Ungureanu, Site 0114
- 电话号码:40742206212
-
-
-
-
District of Columbia
-
Washington D.C.、District of Columbia、美国、20016
- 尚未招聘
- Local Institution - 0183
-
接触:
- Site 0183
-
-
Georgia
-
Athens、Georgia、美国、30607
- 招聘中
- University Cancer & Blood Center, LLC
-
接触:
- Frederick Flynt Jr, Site 0170
- 电话号码:402-334-4773
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- 招聘中
- Baptist Health Lexington
-
接触:
- Firas Badin, Site 0034
- 电话号码:859-276-0414
-
Lexington、Kentucky、美国、40509
- 招聘中
- Baptist Health Hamburg
-
接触:
- Firas Badin, Site 0171
- 电话号码:859-260-6100
-
-
Maryland
-
Baltimore、Maryland、美国、21224
- 尚未招聘
- Local Institution - 0123
-
接触:
- Site 0123
-
-
Mississippi
-
Hattiesburg、Mississippi、美国、39401
- 招聘中
- Hattiesburg Clinic
-
接触:
- John Hrom, Site 0180
- 电话号码:601-261-1700
-
-
Nebraska
-
Grand Island、Nebraska、美国、68803
- 招聘中
- Nebraska Cancer Specialists
-
接触:
- Joel Michalski, Site 0172
- 电话号码:402-955-2691
-
Omaha、Nebraska、美国、68130
- 招聘中
- Oncology Hematology West PC
-
接触:
- Joel Michalski, Site 0102
- 电话号码:402-955-2691
-
-
New York
-
New York、New York、美国、10021
- 尚未招聘
- Local Institution - 0080
-
接触:
- Site 0080
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 尚未招聘
- Local Institution - 0176
-
接触:
- Site 0176
-
-
Texas
-
Houston、Texas、美国、77030
- 尚未招聘
- Local Institution - 0095
-
接触:
- Site 0095
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- 尚未招聘
- Local Institution - 0135
-
接触:
- Site 0135
-
-
-
-
-
Guildford、英国、GU2 7XX
- 招聘中
- The Royal Surrey County Hospital NHS Foundation Trust
-
接触:
- Ali Suwaidan, Site 0037
- 电话号码:01483571122
-
-
BIR
-
Birmingham、BIR、英国、B9 5SS
- 尚未招聘
- Local Institution - 0182
-
接触:
- Site 0182
-
-
Greater London
-
London、Greater London、英国、SE19RT
- 尚未招聘
- Local Institution - 0035
-
接触:
- Site 0035
-
-
-
-
-
Barcelona、西班牙、8036
- 尚未招聘
- Local Institution - 0163
-
接触:
- Site 0163
-
Barcelona、西班牙、08041
- 招聘中
- Hospital de la Santa Creu i Sant Pau
-
接触:
- Margarita Majem Tarruella, Site 0068
- 电话号码:34935565651
-
Barcelona、西班牙、08035
- 招聘中
- Hospital Universitari Vall D'Hebron
-
接触:
- Enriqueta Felip Font, Site 0027
- 电话号码:34932746077
-
Madrid、西班牙、28041
- 撤销
- Local Institution - 0041
-
Majadahonda、西班牙、28222
- 尚未招聘
- Local Institution - 0010
-
接触:
- Site 0010
-
Málaga、西班牙、29010
- 招聘中
- Hospital Carlos Haya De Malaga
-
接触:
- Manuel Cobo-Dols, Site 0020
- 电话号码:00349422033350000
-
-
Barcelona
-
Badalona、Barcelona、西班牙、8916
- 尚未招聘
- Local Institution - 0132
-
接触:
- Site 0132
-
-
Seville
-
Seville、Seville、西班牙、41013
- 尚未招聘
- Local Institution - 0162
-
接触:
- Site 0162
-
-
-
-
-
Buenos Aires、阿根廷、C1426ANZ
- 招聘中
- Instituto Medico Especializado Alexander Fleming
-
接触:
- Claudio Martin, Site 0094
- 电话号码:5491166936669
-
Viedma、阿根廷、R8500ACE
- 招聘中
- Clinica Viedma S.A.
-
接触:
- Ruben Kowalyszyn, Site 0092
- 电话号码:5492920601693
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、2000
- 招聘中
- Sanatorio Parque Rosario
-
接触:
- Gaston Martinengo, Site 0082
- 电话号码:5493416955611
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria
- Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.
- Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Exclusion Criteria
- Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.
- Participants must not have prior treatment with immuno-oncology therapies.
- Participants must not have untreated central nervous system (CNS) metastases.
- Other protocol-defined Inclusion/Exclusion criteria apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Pumitamig + Imzokitug + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
其他名称:
Specified dose on specified days Specified dose on specified days
其他名称:
|
|
实验性的:Arm B: Pumitamig + Imzokitug + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
其他名称:
Specified dose on specified days Specified dose on specified days
其他名称:
|
|
实验性的:Arm C: Pumitamig + Imzokitug + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
其他名称:
Specified dose on specified days Specified dose on specified days
其他名称:
|
|
实验性的:Arm D: Pumitamig + Histology-based PDCT
|
Specified dose on specified days Specified dose on specified days Specified dose on specified days Specified dose on specified days
其他名称:
Specified dose on specified days |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)
大体时间:Up to approximately 4 years
|
Up to approximately 4 years
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
总生存期(OS)
大体时间:最长约 4 年
|
最长约 4 年
|
|
Number of participants with adverse events (AEs)
大体时间:Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with serious adverse events (SAEs)
大体时间:Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with treatment-related AEs
大体时间:Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with treatment-related SAEs
大体时间:Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of participants with AEs leading to discontinuation
大体时间:Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Number of deaths
大体时间:Up to 90 days after discontinuation of study treatment
|
Up to 90 days after discontinuation of study treatment
|
|
Progression free survival (PFS) by investigator (per RECIST v1.1)
大体时间:Up to approximately 4 years
|
Up to approximately 4 years
|
|
Duration of response (DOR) by investigator (per RECIST v1.1)
大体时间:Up to approximately 4 years
|
Up to approximately 4 years
|
|
Time to recurrence (TTR) by investigator (per RECIST v1.1)
大体时间:Up to approximately 4 years
|
Up to approximately 4 years
|
合作者和调查者
调查人员
- 研究主任:Bristol-Myers Squibb、Bristol-Myers Squibb
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CA052-1000
- 2026-525170-19 (其他标识符:EU CT Number)
- U1111-1333-5867 (其他标识符:WHO)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD 共享时间框架
See Plan Description
IPD 共享访问标准
See Plan Description
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.